| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8912210 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8754096 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US10117836 | ALLERGAN | Tablet formulation for CGRP active compounds |
Jan, 2035
(11 years from now) | |
Ubrelvy is owned by Allergan.
Ubrelvy contains Ubrogepant.
Ubrelvy has a total of 5 drug patents out of which 0 drug patents have expired.
Ubrelvy was authorised for market use on 23 December, 2019.
Ubrelvy is available in tablet;oral dosage forms.
Ubrelvy can be used as acute treatment of migraine with headache, with or without aura in adults, acute treatment of migraine with or without aura in adults.
Drug patent challenges can be filed against Ubrelvy from 2023-12-24.
The generics of Ubrelvy are possible to be released after 30 January, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 2023-12-24
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults
Dosage: TABLET;ORAL
UBRELVY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic